Mark Cuban Cost Plus Drugs adds 10th brand-name drug

Mark Cuban Cost Plus Drug Co. added its 10th brand-name drug to its portfolio that includes about 1,000 generics.

Cost Plus Drugs began selling TheracosBio's Brenzavvy (bexagliflozin), an FDA-approved Type 2 diabetes medication, on July 13, according to a news release. Its other branded drugs are IBSA Pharma's Tirosint; Johnson & Johnson's Invokana, Invokamet and Invokamet extended-release; and Pfizer's Duavee, Estring, Premarin, Premphase and Prempro. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars